On 27 May 2026, Real Decreto 415/2026, de 27 de mayo, por el que se regula la evaluación de tecnologías sanitarias was published in the Boletín Oficial del Estado (BOE-A-2026-11587), one day after the Council of Ministers approved it. For the first time, Spain has a single statutory framework governing how medicines, medical devices, diagnostics, digital therapeutics, clinical procedures and new models of care are assessed before — and after — they enter the National Health System (SNS).
The Ministry of Health sold it as a transparency and efficiency reform, and on its own terms it is one. But the headline that travelled fastest was the deadline: a maximum evaluation window of 180 days. Read against the way access actually works in Spain, that number is the most revealing thing in the decree — not because it is ambitious, but because of what it measures and what it cannot.
The most recent EFPIA Patients W.A.I.T. Indicator puts the time from European marketing authorisation to real-world availability of an innovative medicine in Spain at 537 days. That is an improvement — down from 616 the year before — but it sits against an EU average that has climbed to roughly 597 days. The decree’s new clock and that 537-day figure are not the same measurement. Confusing the two is exactly how a procedural reform gets mistaken for an access reform.
What the Royal Decree actually does
Strip away the framing and three structural changes define the new system.
Governance. The decree creates a Consejo de Gobernanza (the HTA Council), housed within the Secretaría de Estado de Sanidad, as the top directing body. It sets strategy, supervises the model and approves the technical guidelines the rest of the system runs on.
Evaluation. Two evaluation offices, framed as functionally independent units, do the scientific work. The Oficina para la Evaluación de Medicamentos sits inside the Spanish Agency of Medicines and Medical Devices (AEMPS). The Oficina para la Evaluación de Tecnologías Sanitarias no Farmacológicas absorbs the existing Network of HTA Agencies (RedETS). Their output is a scientific assessment of clinical and non-clinical value.
Adoption. A third body, the Grupo para la Adopción de las Tecnologías Sanitarias, is the bridge between that scientific assessment and the bodies that actually decide — chiefly the Interministerial Pricing Commission (Comisión Interministerial de Precios de los Medicamentos, CIPM). It produces the final read on a technology’s relative position in the therapeutic scheme.
Two features matter more than the org chart. First, the assessments are preceptivas pero no vinculantes — mandatory to produce, but not binding on the decision-maker. Second, the decree governs evaluation. It does not govern the pricing and reimbursement decision itself. Those two facts are the whole story.
The clock — and exactly what it starts
The decree imposes real deadlines, and they are not trivial. For medicines, the system has 90 calendar days to produce the report on clinical aspects and a further 90 days for the non-clinical aspects — the 180-day figure, assembled from two halves. For non-pharmacological technologies, the ceiling is 180 days outright. Where a European Joint Clinical Assessment (JCA) already exists, the national clinical report must be issued within 15 days of its publication, because the decree prohibits re-running a clinical evaluation the EU has already done. All of these can be extended when a re-evaluation is required.
This is genuinely useful. It gives developers something Spain has never offered: a stated, bounded timeline for the assessment phase, plus the option of voluntary scientific consultations before a product reaches the market, so the evidence package can be shaped early toward what the SNS will actually ask for.
But notice precisely what the clock is timing. It starts when the evaluation procedure is initiated and stops when the assessment report is delivered. It is a stopwatch on the production of an opinion — an opinion that, by the decree’s own terms, no one is obliged to follow.
What 537 days actually measures
The W.A.I.T. indicator does not time the assessment phase. It times the gap between the day the European Commission grants marketing authorisation and the day a medicine is genuinely available to patients — in Spain’s case, listed for reimbursement and reachable on the ground. That interval contains far more than evaluation.
It contains the delay before the national financing and pricing file even opens. It contains the CIPM negotiation over price and reimbursement conditions — the step the decree explicitly does not regulate. And it contains the part most foreign observers underestimate: the rollout across 17 autonomous communities, each of which can add its own therapeutic positioning, tendering and budget-control layer before a drug a national body has “approved” actually appears on a hospital shelf in a given region.
Evaluation was never where most of those 537 days lived. So a system that compresses the evaluation phase to 180 days, and hits that target every time, can coexist with a 537-day wait without contradiction. The clock has been placed on the fast part of the relay. The slow legs — negotiation and regional adoption — keep running on their own schedule.
There is a sharper irony underneath. A 180-day ceiling on pricing and reimbursement decisions is not new to Spain; EU law has notionally imposed one since the Transparency Directive of 1989, split into the same 90-plus-90 structure the decree now echoes for evaluation. Spain overshoots that decision deadline by roughly threefold in practice. Layering a fresh 180-day clock onto the assessment, while leaving the decision clock unenforced, does not obviously change the arithmetic patients live with.
Why “non-binding” is the load-bearing word
A rigorous, transparent, independent assessment is worth having on its own merits, and the decree’s integrity provisions are real: annual public declarations of interest, a bar on evaluators holding economic or professional ties to developers, restrictions where conflicts arise, and public access to participant lists, minutes and final reports. For a system long criticised as opaque, that is a meaningful upgrade in governance.
But an assessment that does not bind the decision changes the negotiating dynamic less than it appears to. The CIPM remains free to price, defer, restrict or decline regardless of what the evaluation office concludes. Farmaindustria, while backing the principle of independent evaluation, flagged precisely this gap: the decree regulates evaluation but stops short of a complete framework that also governs the final financing and pricing decision. It is explicitly a first step — one component of the broader pharmaceutical-legislation package the sector has been waiting on — not the finished architecture.
For a publication that has spent 2026 tracking how Germany, Italy, the UK and France each rewired the link between assessment and decision, Spain’s choice is the notable one: it has built the assessment engine and left the transmission for later.
What this changes for market access teams
Four practical consequences follow for anyone planning a Spanish launch.
Manage two clocks, not one. The 180-day evaluation timeline is now plannable and worth building dossier readiness around — especially the 15-day JCA turnaround, which makes the quality of your EU-level submission directly determinative of the Spanish clinical report. But model the pricing and regional-adoption phases separately and conservatively; the decree does nothing to bind them, and that is still where the calendar is won or lost.
Use the early-dialogue door. Voluntary scientific consultations are a new, low-cost mechanism to learn what the SNS will value before the evidence package is frozen. Treated as a real input rather than a formality, it is the cheapest way to de-risk the non-clinical half of the 90-plus-90 assessment, where Spanish epidemiology, organisational impact and budget framing now sit.
Re-price your evidence for the back end. The decree leans hard on real-world data and periodic re-evaluation, with disinvestment — withdrawal or substitution — explicitly on the table for technologies that stop justifying their place. Access is no longer a single event at launch; it is a position that has to be defended with post-launch evidence.
Audit your KOL and advisory footprint now. Public, annual conflict-of-interest declarations and published minutes change the calculus around who can sit on which panel. The engagement map you have been using may not survive the new transparency regime intact.
The bottom line
Royal Decree 415/2026 is a real institutional advance: a single framework, a transparent process, a stated deadline and a structural fit with the EU HTA Regulation. None of that should be dismissed. But the 180-day clock measures the assessment, not the access. The 537-day wait lives mostly in the pricing negotiation and the seventeen-region rollout the decree leaves untouched — and the report that drives it all binds no one. Spain has built a faster way to produce an opinion. Whether patients wait less now depends entirely on the decision the opinion is supposed to inform, and that decision is still governed by everything this decree chose not to regulate.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.